Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook

This article was originally published in The Tan Sheet

Executive Summary

Merck & Co.’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.

You may also be interested in...



Sensitivity To Flu Helped OTC Drug Firms End 2017 With Sales Boost

Cold and flu products performed “extraordinarily strong” wherever an influenza virus hit hardest, demonstrating “how understanding key incidents can really help tactical support and trade strategies at the local level,” market researcher says at CHPA exec conference.

Sensitivity To Flu Helped OTC Drug Firms End 2017 With Sales Boost

Cold and flu products performed “extraordinarily strong” wherever an influenza virus hit hardest, demonstrating “how understanding key incidents can really help tactical support and trade strategies at the local level,” market researcher says at CHPA exec conference.

OTC Switch Interest Cooled By Study Costs To Update Safety Data

Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS108075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel